The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

Inhibition of deubiquitinase (DUB) activity is a promising strategy for cancer therapy. VLX1570 is an inhibitor of proteasome DUB activity currently in clinical trials for relapsed multiple myeloma. Here we show that VLX1570 binds to and inhibits the activity of ubiquitin-specific protease-14 (USP14...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xin, Mazurkiewicz, Magdalena, Hillert, Ellin-Kristina, Olofsson, Maria Hägg, Pierrou, Stefan, Hillertz, Per, Gullbo, Joachim, Selvaraju, Karthik, Paulus, Aneel, Akhtar, Sharoon, Bossler, Felicitas, Khan, Asher Chanan, Linder, Stig, D’Arcy, Padraig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893612/
https://www.ncbi.nlm.nih.gov/pubmed/27264969
http://dx.doi.org/10.1038/srep26979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893612/
https://www.ncbi.nlm.nih.gov/pubmed/27264969
http://dx.doi.org/10.1038/srep26979

Ejemplares similares